Efficacy and safety of finerenone with SGLT2i in IgA nephropathy
Our study shows that combined finerenone-SGLT2i therapy has a more rapid and superior proteinuria reduction versus monotherapy in IgA nephropathy, with preserved renal function and good safety.
Authors
- Yi Dong (ORCID: https://orcid.org/0000-0002-7993-4150)
- Zihan Zhai
- Sicheng Zhao (ORCID: https://orcid.org/0000-0001-5843-6411)
- Liuwei Wang (ORCID: https://orcid.org/0000-0002-6176-6056)
- Lu Yu (ORCID: https://orcid.org/0000-0001-8378-9112)
- Yanhong Guo (ORCID: https://orcid.org/0000-0002-3334-9159)
- Qiuhong Li
- Lin Tang (ORCID: https://orcid.org/0000-0002-2068-3123)
- Yulin Wang (ORCID: https://orcid.org/0000-0002-3315-1927)
Institutions
- First Affiliated Hospital of Zhengzhou University (CN)
Publication Details
- Journal
- Nephrology Dialysis Transplantation
- Published
- 2025-11-06
- DOI
- https://doi.org/10.1093/ndt/gfaf244
- Citations
- 1
- Primary Topic
- Renal Diseases and Glomerulopathies
- Type
- article
- Field-Weighted Citation Impact
- 1.43